Literature DB >> 3668852

Suppression of inhibitory neural input to colonic circular muscle by opioid peptides.

J R Grider1, G M Makhlouf.   

Abstract

The aim of this study was to identify the neurotransmitter responsible for the dominant inhibitory neural input that normally masks myogenic phasic activity in the intestine. Opioid agonists, including opioid derivatives of proenkephalin and prodynorphin, caused direct tonic and indirect phasic contractions of strips from the circular muscle layer of rat colon. Both contractile responses appeared to be mediated by preferential interaction with delta opioid receptors. Elimination of most, if not all, neural input with tetrodotoxin (TTX) induced concentration-dependent phasic contractions. Neutralization of background vasoactive intestinal peptide (VIP) with VIP antiserum induced phasic contractions in previously quiescent muscle strips. The effect of VIP antiserum was concentration-dependent in the range of 1:960 to 1:60. A threshold concentration of VIP antiserum (1:960) increased the sensitivity of the phasic responses to [Met]enkephalin (100-fold) and TTX (20-fold) whereas exogenous VIP had the opposite effect. [Met]enkephalin and TTX inhibited basal VIP release by 43 +/- 8% (P less than .001) and 65 +/- 13% (P less than .01), respectively. It was concluded that VIP was the neurotransmitter responsible for the dominant inhibitory neural input to intestinal circular muscle and that opioid peptides induce phasic contractions by suppressing VIP release.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3668852

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Effect of opioid peptides on circular muscle of canine duodenum.

Authors:  A J Bauer; J H Szurszewski
Journal:  J Physiol       Date:  1991-03       Impact factor: 5.182

Review 2.  Site and mechanism of morphine tolerance in the gastrointestinal tract.

Authors:  H I Akbarali; A Inkisar; W L Dewey
Journal:  Neurogastroenterol Motil       Date:  2014-10       Impact factor: 3.598

3.  Effect of vasoactive intestinal polypeptide on the release of serotonin from the in vitro vascularly perfused small intestine of guinea pig.

Authors:  H Schwörer; K Racké; H Kilbinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

4.  The role of β-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract.

Authors:  Minho Kang; Hercules T Maguma; Tricia H Smith; Gracious R Ross; William L Dewey; Hamid I Akbarali
Journal:  J Pharmacol Exp Ther       Date:  2011-11-30       Impact factor: 4.030

5.  Differences in the characteristics of tolerance to μ-opioid receptor agonists in the colon from wild type and β-arrestin2 knockout mice.

Authors:  Hercules T Maguma; William L Dewey; Hamid I Akbarali
Journal:  Eur J Pharmacol       Date:  2012-04-11       Impact factor: 4.432

6.  Regulation of neural responses in the canine pyloric sphincter by opioids.

Authors:  O Bayguinov; K M Sanders
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

7.  Morphine tolerance in the mouse ileum and colon.

Authors:  Gracious R Ross; Bichoy H Gabra; William L Dewey; Hamid I Akbarali
Journal:  J Pharmacol Exp Ther       Date:  2008-08-05       Impact factor: 4.030

8.  Deletion of IP3R1 by Pdgfrb-Cre in mice results in intestinal pseudo-obstruction and lethality.

Authors:  Hong Wang; Ran Jing; Christa Trexler; Yali Li; Huayuan Tang; Zhixiang Pan; Siting Zhu; Beili Zhao; Xi Fang; Jie Liu; Ju Chen; Kunfu Ouyang
Journal:  J Gastroenterol       Date:  2018-10-31       Impact factor: 7.527

9.  Chronic Morphine Induces IL-18 in Ileum Myenteric Plexus Neurons Through Mu-opioid Receptor Activation in Cholinergic and VIPergic Neurons.

Authors:  Karan H Muchhala; Eda Koseli; Aravind R Gade; Kareem Woods; Suha Minai; Minho Kang; A Rory McQuiston; William L Dewey; Hamid I Akbarali
Journal:  J Neuroimmune Pharmacol       Date:  2022-02-02       Impact factor: 7.285

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.